Clinical trial · Observational
Prognostic Evaluation of Tumor Volume and Its Changes in Radical Radiotherapy of Advanced NSCLC
Multicentric Retrospective Prognostic Evaluation of Tumor Volume and Their Change in the Curative-intended, Radical Radiotherapy of Locally Advanced NSCLC
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of the study is to retrospectively monitor the 'gross tumor volume' (GTV) before initiation of radiotherapy and its changes during radiotherapy and to correlate them with retrospectively recorded patient data, as well as with prognostic and therapeutic outcome after definite radiotherapy of locally advanced NSCLC in stage UICC III.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non Small Cell Lung Cancer Stage III | Lung Non-Small Cell Carcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- Locally advanced NSCLC-patients
- description
- Inoperable stage III (A and B) non-small-cell lung cancer (NSCLC) with indication for radical radiotherapy.
Primary outcomes (1)
- measure
- Overall Survival (months)
- timeFrame
- 5 months
- description
- from the start of Radiotherapy until death / last seen during follow up
Secondary outcomes (3)
- measure
- Absolute Basal Gross Tumor Volume (ml) before Radiotherapy (GTV1)
- timeFrame
- 5 months
- description
- in ml (cc) as detected by initial planning CT or diagnostic CT before the start of RT
- measure
- Absolute Gross Tumor Volume before Radiation Boost (GTV2)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 100 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed NSCLC (Adeno / SCC) Stage UICC III A or B * CT based radiation treatment planning (PET- or PET-CT-based if available) * completed curative-intended radiotherapy ± chemotherapy (achieved total dose ≥ 60 Gy normofractionated or ≥ 50 Gy hypofractionated) Exclusion Criteria: * Stereotactic radiotherapy * Second malignancy \<5 years before diagnosis of NSCLC * Pleural effusion ipsilateral, extensive atelectasis ipsilateral
References
Publications (0)
Data not yet available